Want to see IONS full AI Analyst Report?

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

1,544 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IONS Analyst Ratings

Strong Buy

17 Buy

2 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Ionis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$104.61

▲(38.17% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $104.61 with a high forecast of $130.00 and a low forecast of $75.00. The average price target represents a 38.17% change from the last price of $75.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","82":"$82","131":"$131","57.5":"$57.5","106.5":"$106.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104.61111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$104.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,57.5,82,106.5,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.38,79.58153846153846,83.78307692307692,87.98461538461538,92.18615384615384,96.3876923076923,100.58923076923077,104.79076923076923,108.99230769230769,113.19384615384615,117.39538461538461,121.59692307692308,125.79846153846154,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.38,77.628547008547,79.87709401709401,82.12564102564102,84.37418803418804,86.62273504273504,88.87128205128205,91.11982905982906,93.36837606837607,95.61692307692309,97.8654700854701,100.1140170940171,102.36256410256411,{"y":104.61111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.38,75.35076923076923,75.32153846153845,75.29230769230769,75.26307692307692,75.23384615384614,75.20461538461538,75.17538461538462,75.14615384615385,75.11692307692307,75.08769230769231,75.05846153846154,75.02923076923076,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.96,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.38,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$130.00

Average Price Target$104.61

Lowest Price Target$75.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eliana Merle

Barclays

$115

Buy

51.90%

Upside

Reiterated

06/26/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Ionis Pharmaceuticals (NASDAQ: IONS)

Joseph Stringer

Needham

$105

Buy

38.69%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), Climb Bio (NASDAQ: CLYM) and Ionis Pharmaceuticals (NASDAQ: IONS)

Mitchell Kapoor

H.C. Wainwright

$125→$130

Buy

71.71%

Upside

Reiterated

06/25/26

Ionis Pharmaceuticals price target raised to $130 from $125 at H.C. WainwrightIonis Pharmaceuticals price target raised to $130 from $125 at H.C. Wainwright

Yanan Zhu

Wells Fargo

$100

Buy

32.08%

Upside

Reiterated

06/25/26

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Myles Minter

William Blair

―

Buy

―

Reiterated

06/24/26

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

Yaron Werber

TD Cowen

$108

Buy

42.65%

Upside

Reiterated

06/24/26

Analysts Are Bullish on These Healthcare Stocks: Inmune Bio (INMB), AbSci (ABSI)

Jason Gerberry

Bank of America Securities

$111

Buy

46.61%

Upside

Reiterated

06/24/26

Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Ionis Pharmaceuticals (IONS)

Jessica Fye

J.P. Morgan

$80→$90

Buy

18.87%

Upside

Reiterated

06/24/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and InMode (NASDAQ: INMD)

Salveen Richter

Goldman Sachs

$74→$75

Hold

-0.94%

Downside

Reiterated

06/24/26

Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman SachsIonis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

Michael Ulz

Morgan Stanley

$130

Buy

71.71%

Upside

Reiterated

06/24/26

Analyst Reiterates Buy on Tryngolza Launch Momentum; Maintains $130 Price Target

Gary Nachman

Canaccord Genuity

$110

Buy

45.29%

Upside

Reiterated

06/24/26

Ionis Buy Rating Reiterated as Tryngolza Launch Underpins Multibillion-Dollar Opportunity and Unchanged $110 Price Target

Akash Tewari

Jefferies

$113

Buy

49.25%

Upside

Reiterated

06/15/26

Jefferies Remains a Buy on Ionis Pharmaceuticals (IONS)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$106

Buy

40.01%

Upside

Reiterated

06/05/26

Ionis Pharmaceuticals (IONS) Receives a Buy from Guggenheim

Eric Joseph

Citi

$90

Buy

18.87%

Upside

Initiated

05/20/26

J.P. Morgan Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Paul Matteis

Stifel Nicolaus

$83→$86

Hold

13.59%

Upside

Reiterated

04/30/26

Stifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eliana Merle

Barclays

$115

Buy

51.90%

Upside

Reiterated

06/26/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Ionis Pharmaceuticals (NASDAQ: IONS)

Joseph Stringer

Needham

$105

Buy

38.69%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), Climb Bio (NASDAQ: CLYM) and Ionis Pharmaceuticals (NASDAQ: IONS)

Mitchell Kapoor

H.C. Wainwright

$125→$130

Buy

71.71%

Upside

Reiterated

06/25/26

Ionis Pharmaceuticals price target raised to $130 from $125 at H.C. WainwrightIonis Pharmaceuticals price target raised to $130 from $125 at H.C. Wainwright

Yanan Zhu

Wells Fargo

$100

Buy

32.08%

Upside

Reiterated

06/25/26

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Myles Minter

William Blair

―

Buy

―

Reiterated

06/24/26

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

Yaron Werber

TD Cowen

$108

Buy

42.65%

Upside

Reiterated

06/24/26

Analysts Are Bullish on These Healthcare Stocks: Inmune Bio (INMB), AbSci (ABSI)

Jason Gerberry

Bank of America Securities

$111

Buy

46.61%

Upside

Reiterated

06/24/26

Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Ionis Pharmaceuticals (IONS)

Jessica Fye

J.P. Morgan

$80→$90

Buy

18.87%

Upside

Reiterated

06/24/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and InMode (NASDAQ: INMD)

Salveen Richter

Goldman Sachs

$74→$75

Hold

-0.94%

Downside

Reiterated

06/24/26

Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman SachsIonis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

Michael Ulz

Morgan Stanley

$130

Buy

71.71%

Upside

Reiterated

06/24/26

Analyst Reiterates Buy on Tryngolza Launch Momentum; Maintains $130 Price Target

Gary Nachman

Canaccord Genuity

$110

Buy

45.29%

Upside

Reiterated

06/24/26

Ionis Buy Rating Reiterated as Tryngolza Launch Underpins Multibillion-Dollar Opportunity and Unchanged $110 Price Target

Akash Tewari

Jefferies

$113

Buy

49.25%

Upside

Reiterated

06/15/26

Jefferies Remains a Buy on Ionis Pharmaceuticals (IONS)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$106

Buy

40.01%

Upside

Reiterated

06/05/26

Ionis Pharmaceuticals (IONS) Receives a Buy from Guggenheim

Eric Joseph

Citi

$90

Buy

18.87%

Upside

Initiated

05/20/26

J.P. Morgan Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

Paul Matteis

Stifel Nicolaus

$83→$86

Hold

13.59%

Upside

Reiterated

04/30/26

Stifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

3 Months

Myles MinterWilliam Blair

Success Rate

15/19 ratings generated profit

Average Return

+17.93%

Copying Myles Minter's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +17.93% per trade.

1 Year

Myles MinterWilliam Blair

Success Rate

16/19 ratings generated profit

Average Return

+38.97%

Copying Myles Minter's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +38.97% per trade.

2 Years

Yanan ZhuWells Fargo

Success Rate

24/26 ratings generated profit

Average Return

+64.83%

Copying Yanan Zhu's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +64.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IONS has received 50 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IONS average Analyst price target in the past 3 months is 104.61.

Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$1.06 with a range of -$1.26 to -$0.82. The previous quarter’s EPS was -$0.56. IONS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $190.53M with a range of $162.90M to $211.00M. The previous quarter’s sales results were $246.09M. IONS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IONS has Performed in-line its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?

Based on analyst ratings, Ionis Pharmaceuticals Inc.’s 12-month average price target is 104.61.

What is IONS’s upside potential, based on the analysts’ average price target?

Ionis Pharmaceuticals Inc. has 38.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IONS a Buy, Sell or Hold?

Ionis Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.

What is Ionis Pharmaceuticals Inc.’s price target?

The average price target for Ionis Pharmaceuticals Inc. is 104.61. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $130.00 ,the lowest forecast is $75.00. The average price target represents 38.17% Increase from the current price of $75.71.

What do analysts say about Ionis Pharmaceuticals Inc.?

Ionis Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of IONS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

IONS Analyst Ratings

IONS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ionis Pharmaceuticals

IONS Analyst Recommendation Trends

IONS Financial Forecast

IONS Earnings Forecast

IONS Sales Forecast

IONS Stock Forecast FAQ

Detailed List of Analyst Forecasts